Alzheimer's disease: An overview of research and clinical advances

Managed Care Interface

Volumn 20, Issue 3, 2007, Pages 20-23

  Libow, Leslie S ^a  

^a Jewish Home and Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMYLOID; AMYLOID PRECURSOR PROTEIN; CHOLINESTERASE INHIBITOR; MEMANTINE; NEUROLEPTIC AGENT;

AGING; ALZHEIMER DISEASE; BEHAVIOR; CLINICAL FEATURE; CLINICAL RESEARCH; COGNITIVE DEFECT; DEMENTIA; DIAGNOSTIC APPROACH ROUTE; DISEASE MARKER; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; NEUROFIBRILLARY TANGLE; NEUROIMAGING; PREVALENCE; REVIEW; SURVIVAL; SYNAPTIC POTENTIAL;

AGED; ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; BRAIN; COMPLEMENTARY THERAPIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; RESEARCH SUPPORT;

EID: 33947583272     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (16)

1. Progress Report on Alzheimer's Disease, 2004-2005: New Discoveries, New Insights. U.S. Dept. of Health and Human Services publication No. (NIH) 05-5724. Washington, DC, National Institutes of Health, November 2005.
2. Grundman M, Petersen RC, Ferris SH, et al: Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66.
3. Cleary JP, Walsh DM, Hofmeister JJ, et al: Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. Nat Neurosci 2005;8:79-84.
4. Lacor PN, Buniel MC, Chang L, et al: Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004;24:10190-10200.
5. Galasko D: Biomarkers for Alzheimer's disease-clinical needs and application. J Alzheimers Dis 2005;8:339-346.
6. Gilman S, Koller M, Black RS: Clinical effects of A beta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005;64:1553-1562.
7. Small GW, Kepe V, Ercoli LM, et al: PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-2663.
8. Alexopoulos GS, Jeste DV, Chung H, et al: The expert consensus guidelines series. Treatment of dementia and its behavioral disturbances. Postgrad Med 2005;Jan(Spec. No):6-22.
9. Reisberg B, Doody R, Stoffler A, et al: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
10. Morris MC, Evans DA, Bienias JL, et al: Dietary fats and the risk of incident Alzheimer disease. Arch Neurol 2003;60:194-200.
11. Morris MC, Evans DA, Bienias JL, et al: Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 2003;60:940-946.
12. Korf ES, White LR, Scheltens P, et al: Midlife blood pressure and the risk of hippocampal atrophy: The Honolulu-Asia Aging Study. Hypertension 2004;44:29-34.
13. Lee S, Kawachi I, Berkman LF, et al: Education, other socioeconomic indicators, and cognitive function. Am J Epidemiol 2003;157:712-720.
14. Verghese J, Lipton RB, Katz MJ, et al: Leisure activities and the risk of dementia in the elderly. N Engl J Med 2003;348:2508-2516.
15. Honig LS, Tang MX, Albert S, et al: Stroke and the risk of Alzheimer disease. Arch Neurol 2003;60:1701-1712.
16. Yaffe K, Kanaya A, Lindquist K, et al: The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004;292:2237-2242.